Provectus Announces Updated Results from Phase 1B Trial of PV-10 in Combination with KEYTRUDA® for Treatment of Advanced Melanoma at ASCO 2019
03 juin 2019 16h05 HE
|
Provectus Biopharmaceuticals Inc.
No safety concerns identified; no significant overlap of or unexpected toxicities65% overall ORR with 9% CR (RECIST 1.1) maintainedPreliminary PFS of 12.3 monthsChanges in T cell populations similar...